ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/ovarian/advanced/platinum-sensitive
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gynaecological / Ovarian - Advanced / Platinum-sensitive
2
trial(s) found.
NCT07213804
Advanced
Phase 3
Recruiting
FRAmework-01
: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in
Platinum-Sensitive
Ovarian Cancer.
anti-FR-alpha antibody-drug conjugate
anti-VEGF monoclonal antibody
Carcinoma
Ovarian cancer
Primary fallopian tube serous carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
TAS
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT06824467
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With
Platinum-sensitive
Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103) (
2870-022
)
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
Fallopian tube cancer
Ovarian cancer
Primary peritoneal serous carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Recruitment Country and State
NSW (2)
QLD (2)
VIC (2)
TAS (1)
Phase
Phase 3 (2)
Trial Type
Advanced (2)
Cancer Therapy Class
VEGF
100%
FR-alpha
50%
Trop2
50%
Facility
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
3002 - East Melbourne - Epworth Freemasons (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
Cancer Type
Cancer
Fallopian tube cancer
Gynaecological cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Solid tumour
Carcinoma
Epithelial Ovarian Cancer
Primary fallopian tube serous carcinoma
Peritoneal cancer
Primary peritoneal serous carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy